GSK's Blood Cancer Drug Faces US Setback Due To FDA Panel's Eye Safety Warning

Silver,Spring,,Md,,Usa,-,June,25,,2022:,The,Fda

The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit/risk profile at the proposed dosage of GSK plc’s (NYSE:GSK) Blenrep (belantamab mafodotin-blmf) combinations.

The belantamab mafodotin combinations were evaluated in adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.